About us

Meinrad Good is founder and Managing Director of Target BioScience AG. He has extensive knowledge and experience in the pharmaceutical industry sector and has performed a number of consulting projects on a national and international level in scientific and regulatory affairs, quality assurance and business development. Meinrad Good has a PhD degree in Biochemistry and an advanced degree in General Management, both from the University of Zurich.

Maria Heimgartner has joined Target BioScience AG as a senior consultant in 2012 and serves now as a Principal Consultant in quality assurance, market access and business development. Prior to joining Target BioScience Maria Heimgartner has served as a General Manager for Genzyme Switzerland, a global biopharmaceutical company focused on rare diseases and multiple sclerosis. Maria Heimgartner brings over 15 years of pharmaceutical industry experience. Maria Heimgartner holds PhD degree from University of Munich and Bachelor of Science degree from University of Houston, Texas.

Monika Lenzer serves as a Consultant in regulatory affairs and as a responsible person for quality management in Good Distribution Practice (GDP) and Good Manufacturing Practice (GMP). She has broad experiences as a practical pharmacist since 2004 and as consultant for regulatory affairs since 2007. Monika Lenzer holds a Master degree as a pharmacist from the Ludwigs-Maximillian-University in Munich.

Urs Heimgartner serves as a Consultant of Pricing & Reimbursement for Target BioScience AG. He has been an employee at Bayer (Schweiz) AG for 26 years and has served in many different functions, most recently as Head of Market Access. He has hands on experience in brining innovative products, despite the challenging environment, on the Reimbursement List (SL) of the BAG.  Prior, he was Business Unit Manager Oncology and Hematology and successfully launched many pharmaceutical products such as Xarelto, Xofigo, Adempas, Stivarga and Kogenate SF. Urs Heimgartner has a PhD degree in Biotechnology from the ETH Zürich.

Jürgen Regenold has been on the Advisory Board of Target BioScience AG since 2006. He is the founder and CEO of the global regulatory affair company Dr. Regenold GmbH as well as the founder of global regulatory group regulanet^®. Jürgen Regenold manages all aspects of the business from strategic product development to regulatory affairs and market access. Previously he served in management of pharmaceutical product development and regulatory affairs. Jürgen Regenold holds a PhD degree as a pharmacist from the Albert-Ludwigs-University of Freiburg.

Patrik Frei has been on the Advisory Board of Target BioScience AG since 2006. He is the founder and CEO of Venture Valuation AG, Switzerland. Since then he has been involved in over 350 valuations for investors as well as biotech, Pharma and medtech companies. He is also the Chairman of Ophthalmopharma, a Swiss based biotech ophthalmology company and a board member of Kleinkraftwerk Birseck AG (KKBN:Berne) a publicly quoted cleantech company. Patrik Frei graduated from the Business University of St. Gallen and completed his PhD thesis at the Swiss Federal Institute of Technology in Lausanne.

Patrick Kolb has been on the Advisory Board of Target BioScience AG since 2021. He is a Biotech startup expert in Europe with a strong focus on Germany, Austria and Switzerland. He has both global and local experience in General Management, Marketing, Sales, Medical Affairs and Market Access. Patrick Kolb has served as General Manager for Intercept, Astellas and Arvelle for Germany, Switzerland and Austria. His area of expertise are mainly focused on orphan medicinal products in various therapeutic fields, including Oncology. He holds an EMBA from HULT International Business Scholl and an MSc in Biology from University of Zurich.